Overview

Phase II Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Chronic Myeloid Leukemia (CML) Philadelphia Chromosome-positive (Ph+)

Status:
Unknown status

Trial end date:
2013-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the hematological, cytogenetic and molecular response to continuous-use of Imatinib in children with CML Ph+.

Phase:

Phase 2

Details

Lead Sponsor:

Renato Melaragno

Treatments:

Imatinib Mesylate